LAMP1 Modulates CXCL10-CXCR3 Axis in Macrophage Polarization
2026-06-11
This study reveals that LAMP1 regulates how the CXCL10-CXCR3 axis directs macrophage polarization, with distinct effects in inflammatory and non-inflammatory states. By using the CXCR3 antagonist AMG 487, the authors dissect autophagy-dependent mechanisms and demonstrate a protective effect against acute lung injury, providing new insights for inflammation research.
3-Bromopyruvate Restores Cetuximab Sensitivity via Autophagy
2026-06-10
This study demonstrates that combining 3-bromopyruvate with cetuximab overcomes resistance in colorectal cancer cells by activating autophagy-dependent ferroptosis. The findings provide a mechanistic rationale and experimental evidence for targeting FOXO3a-mediated pathways to improve treatment outcomes in resistant CRC models.
Prestained Protein Marker: Triple Color Precision for SDS-PA
2026-06-10
The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) from APExBIO transforms SDS-PAGE and Western blot workflows with vivid, triple-color bands and unmatched compatibility for advanced applications. Its EDTA-free design supports phosphoprotein analysis and fluorescent imaging, offering clarity and reproducibility beyond traditional ladders.
α2-AR Agonists Reduce Osteosarcoma Recurrence by Immune Modu
2026-06-09
This study demonstrates that α2-adrenergic receptor agonists, delivered via a thermo-sensitive hydrogel, significantly lower post-surgical osteosarcoma recurrence by boosting immune-mediated anti-tumor responses. The work provides mechanistic insight into T cell activation pathways and suggests a new direction for immune rejection modulation in osteosarcoma therapy.
Optimizing Protein Assays with FLAG tag Peptide (DYKDDDDK):
2026-06-09
This article delivers practical, scenario-driven insight into the use of FLAG tag Peptide (DYKDDDDK) (SKU A6002), emphasizing its impact on reproducibility and workflow efficiency for cell-based and protein detection assays. Drawing on recent literature and product-specific data, it guides researchers in leveraging this peptide for reliable recombinant protein purification and detection.
Urolithin A in Mitochondrial Biogenesis Research: Workflows
2026-06-08
Urolithin A, a gut microbiota-derived metabolite, is transforming mitochondrial biogenesis and anti-inflammatory research with its precise mitophagy activation and reliable performance. This guide breaks down experimental workflows, troubleshooting strategies, and the latest insights from liver fibrosis research, empowering labs to maximize data quality and reproducibility.
Enzyme and Transporter-Mediated DDI Risk in 2022 FDA Drugs
2026-06-08
This article examines a comprehensive mechanistic analysis of enzyme- and transporter-mediated drug-drug interactions (DDIs) for small molecules approved by the FDA in 2022. The study’s integration of in vitro, in silico, and clinical data establishes a framework for understanding DDI risk—highlighting Oteseconazole (VT-1161) as a selective inhibitor with a distinct interaction profile relevant to antifungal research.
Doxorubicin Hydrochloride: Workflow Optimization in Chemothe
2026-06-07
Doxorubicin hydrochloride (Adriamycin HCl) remains a gold standard for modeling both cytotoxicity and cardiotoxicity in cancer research. This article bridges cutting-edge dual-loaded liposome technology, validated protocols, and troubleshooting insights to maximize experimental rigor and translational relevance.
Brefeldin A: Enabling Precision Dissection of Endothelial St
2026-06-06
Explore how Brefeldin A (BFA) empowers researchers to dissect ER stress and cytoskeletal remodeling in endothelial injury and cancer models. This in-depth analysis uniquely connects BFA’s mechanistic action to biomarker discovery in sepsis and advanced cancer research.
Y-27632 dihydrochloride: Rethinking ROCK Inhibition in Epith
2026-06-05
Discover how Y-27632 dihydrochloride, a potent ROCK inhibitor, transforms our understanding of epithelial mechanics and disease modeling. This article uniquely integrates cutting-edge evidence from tissue contractility research to offer advanced assay guidance.
AMG 487: Precision CXCR3 Antagonism for Macrophage Assays
2026-06-05
AMG 487 redefines selective CXCR3 inhibition, enabling high-confidence macrophage polarization studies across inflammatory contexts. Its quantified, reproducible activity underpins translational workflows for inflammation and acute lung injury research, supported by recent breakthroughs in autophagy and phenotype switching.
Ginsenoside Rg1: Optimizing Neuroprotection Research Workflo
2026-06-04
Ginsenoside Rg1, a triterpene saponin from Panax, stands out for its ability to restore neuroimmune balance after anesthesia-induced disruption—making it a cornerstone for neuroprotection and inflammation research. Discover workflow enhancements, protocol parameters, and troubleshooting strategies that maximize reproducibility and mechanistic insight.
Stattic STAT3 Inhibitor: Protocols and Innovations in HNSCC
2026-06-04
Stattic, a selective STAT3 inhibitor from APExBIO, is transforming head and neck squamous cell carcinoma (HNSCC) research by enabling precise modulation of STAT3-dependent pathways. This article delivers actionable protocols, advanced troubleshooting, and insights from the latest studies—empowering researchers to drive breakthroughs in apoptosis induction and radiosensitization.
Flubendazole: Optimizing Autophagy Modulation in Cancer Rese
2026-06-03
Flubendazole (methyl N-[6-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate) stands out as a high-purity, DMSO-soluble autophagy activator that empowers reproducible cancer biology and neurodegenerative disease research. This guide translates in vitro evidence and advanced protocol strategies into actionable workflows, ensuring reliable autophagy signaling pathway modulation and robust drug response evaluation.
Clozapine N-oxide (CNO): Precision Chemogenetic Tool in Neur
2026-06-03
Clozapine N-oxide (CNO) is a biologically inert metabolite of clozapine, widely used as a chemogenetic actuator in neuroscience research for precise neuronal activity modulation. Its selective activation of engineered DREADDs enables non-invasive, reversible control of neuronal circuits, providing robust specificity with minimal off-target effects. Supplied by APExBIO, CNO is recognized for high purity and reliability in GPCR signaling studies.
466 records 16/32 page Previous Next First page 上5页 1617181920 下5页 Last page